{"filings":[{"id":110628,"accession_number":"0001213900-26-018819","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Abpro receives Nasdaq delisting notice for failing minimum equity rule; trading to suspend Feb 23","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Panel notified Abpro on Feb 18, 2026 that it failed to demonstrate compliance with Listing Rule 5550(b)(1) by Feb 16 deadline.","Trading of ABP common stock and ABPWW warrants will be suspended at the open on February 23, 2026.","Company expects to appeal Panel decision within 15 days; if no appeal, Nasdaq will file Form 25 to deregister securities.","If delisted, common stock and warrants are expected to trade on OTC Pink Market under existing symbols, with no assurance of liquidity.","CEO Miles Suk signed the filing; no financial or operational details provided beyond the delisting notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110627,"accession_number":"0001213900-26-014903","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Abpro receives Nasdaq delisting notices after board resignations; appoints two independent directors","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Directors Eisenberg (Jan 28) and Lee (Jan 30) resigned from board and all committees.","Nasdaq notified Feb 5: non-compliant with majority independent director and audit committee rules; no cure period due to multiple vacancies.","Separate Nasdaq notice: compensation committee non-compliance; cure period until Jan 2027 or Jul 2026.","On Feb 9, board appointed M. Fatih Karatas and Mary Gunn as Class II directors, serving on all three committees.","Listing not immediately affected but delisting risk remains; company must respond to Nasdaq by Feb 12."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110626,"accession_number":"0001213900-26-011462","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two directors of Abpro Holdings resign; board to fill vacancies","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anthony D. Eisenberg resigned from Board and all committees on Jan 28, 2026.","Sooyoung Lee resigned from Board and all committees on Jan 30, 2026.","Both resignations are not due to any disagreement with the Company.","Board has started process to identify and appoint qualified independent directors to meet Nasdaq requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110625,"accession_number":"0001213900-26-007215","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["1.01","2.03","5.02","9.01"],"status":"ready","headline":"Abpro Holdings gets $147K CEO loan for D&O insurance; director replaced","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Miles Suk lends $147,000 unsecured to fund D&O insurance premium; 9-month term, 3-month interest-free, then SOFR+2%.","Director Ian McDonald resigned Jan. 16, not due to any disagreement with company.","Dr. Byung-Hak Yoon appointed Class I director to fill vacancy; will serve on Audit, Compensation, and Nominating committees.","Dr. Yoon, age 51, is CEO of OQPBIOM and Doowon Science Pharma; extensive pharma experience.","Loan is solely for insurance premium; no prepayment penalty, no collateral."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110624,"accession_number":"0001213900-26-001570","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Abpro and Celltrion announce FDA IND clearance for lead multispecific antibody ABP-102 / CT-P72","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for ABP-102 / CT-P72, a multispecific HER2 × CD3 T-cell engager targeting HER2-positive solid tumors.","Phase 1 clinical trial anticipated to commence in H1 2026, led by Celltrion under co-development collaboration.","Preclinical data showed selective antitumor activity in HER2-high models and was well tolerated in NHP studies up to 80 mg/kg.","Candidate designed to enhance tumor selectivity and limit activity in HER2-low tissues, aiming to reduce cytokine release syndrome risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127250,"accession_number":"0001213900-25-121446","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Abpro submits IND to FDA for phase 1 trial of ABP-102/CT-P72 in HER2+ cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IND filed for ABP-102/CT-P72, a HER2×CD3 T cell engager targeting HER2-positive solid tumors.","Co-developed with Celltrion; phase 1 start expected in 1H 2026 pending FDA clearance.","Preclinical data presented at AACR 2025 and SITC 2025 showed selective activity in HER2-high tumor models.","First IND submission by Abpro for a solid tumor indication, advancing its immuno-oncology pipeline.","Phase 1 study will evaluate safety, PK, and preliminary efficacy in dose-escalation and expansion cohorts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127249,"accession_number":"0001213900-25-119439","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Abpro Holdings granted Nasdaq extension to regain listing compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received extension from Nasdaq Hearings Panel to achieve full compliance; deadline not specified.","Completed reverse stock split on Nov 3; plans to increase stockholders' equity and may transfer markets.","Has access to up to $44M in equity financing to fund operations and milestones through 2026.","Achieved ~60% reduction in operating expenses vs prior year; lead candidate ABP-102 on track for 2026 first-in-human trials.","Lead candidate ABP-102 developed with Celltrion; DiversImmune and MultiMab platforms advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127248,"accession_number":"0001213900-25-105590","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Abpro/Celltrion present top-ranked preclinical data for CT-P72/ABP-102 at SITC 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Poster selected as Top 150 abstract out of >1,300 submissions at SITC 2025.","CT-P72/ABP-102 shows potent anti-tumor activity in HER2-high models including Enhertu-resistant tumors.","Dual-affinity engineering reduces off-tumor activation; favorable safety in monkeys up to 90 mg/kg.","Data supports advancement toward first-in-human trial planned for next year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127241,"accession_number":"0001213900-25-105733","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K/A","filed_at":"2025-11-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Abpro/Celltrion present preclinical data for CT-P72/ABP-102 at SITC 2025; poster in top 150","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Poster selected as one of Top 150 abstracts out of >1,300 submissions at SITC 2025.","CT-P72/ABP-102 demonstrated potent anti-tumor activity in HER2-high models, including Enhertu-resistant tumors.","Dual-affinity engineering reduced on-target/off-tumor activity; favorable safety in non-human primates.","Data supports advancement toward IND and first-in-human trial planned for next year.","Built on Abpro's DiversImmune® platform for rapid engineering of next-generation antibodies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127247,"accession_number":"0001213900-25-104887","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Abpro announces 1-for-30 reverse stock split effective Oct 31, 2025; trading begins Nov 3","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse stock split effective 5:01 p.m. ET Oct 31; stock trades split-adjusted from Nov 3 under ticker ABP.","Outstanding shares reduced from ~81.2M to ~2.7M; fractional shares rounded up to next whole share.","Company achieved ~60% reduction in operating costs versus same period 2024 through cost optimization.","Celltrion partnership funds ABP-102 development; first-in-human trial expected in 2026.","Reverse split intended to maintain Nasdaq listing and position for next growth phase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127246,"accession_number":"0001213900-25-101285","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Abpro Holdings to effect 1-for-30 reverse stock split, reducing shares from 81.15M to ~2.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio 1:30, effective Oct 31, 2025 at 5:01 p.m. EDT.","Outstanding shares reduced from ~81.15M to ~2.705M; no fractional shares, rounding up.","Trading on adjusted basis begins Nov 3, 2025; ticker ABP unchanged; new CUSIP 000847202.","Stockholder approval obtained at 2025 annual meeting on Oct 10, 2025.","Warrant exercise prices and shares underlying warrants adjusted proportionally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127245,"accession_number":"0001213900-25-099970","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Abpro fails to regain compliance with Nasdaq MVPHS and MVLS; hearing Oct 30","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Notice on Oct 14, 2025 that it did not regain MVPHS ($15M) or MVLS ($50M) compliance by Oct 7 deadline.","Hearing for Minimum Bid Price non-compliance scheduled for October 30, 2025 before Nasdaq Panel.","Delisting action stayed pending Panel decision; no immediate effect on ABP common stock or warrant listing.","Company will present compliance plans at hearing; no assurance of continued listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127244,"accession_number":"0001213900-25-098341","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Abpro Holdings shareholders approve 1-for-30 reverse stock split at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Ian McDonald as Class I director with 30,544,989 votes for, 8,122,953 withheld, and 10,863,999 broker non-votes.","Ratification of Wolf & Company, P.C. as auditor for FY 2025 passed with 48,873,247 votes for, 380,320 against, 278,374 abstentions.","Reverse stock split at 1-for-30 ratio approved with 26,657,935 votes for; no votes against, abstentions, or broker non-votes reported.","Approximately 61.8% of outstanding shares (49,531,941 votes) were represented, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127243,"accession_number":"0001213900-25-096096","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Abpro Holdings receives Nasdaq delisting notice for minimum bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["180-day compliance period ended Sep 29, 2025; bid price remained below $1.00.","Notice received Sep 30; delisting scheduled for Oct 9, 2025 unless appeal filed.","Company intends to request a hearing by Oct 7, 2025, which would stay delisting.","No assurance that the Nasdaq Panel will grant continued listing or extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127242,"accession_number":"0001213900-25-095408","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Abpro Holdings furloughs CMO Robert Markelewicz; termination effective Nov 30, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Robert J. Markelewicz, Jr. furloughed effective Sept 30, 2025; will perform no duties until Nov 30.","Employment terminated effective November 30, 2025.","Furlough and termination reported under Item 5.02 for departure of officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144042,"accession_number":"0001213900-25-067345","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Abpro enters consulting agreement with CEO Miles Suk's entity; $300K annual fee, 500K RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["BioCelsus International (wholly owned by Miles Suk) hired as consultant for CEO services; annual base fee $300,000 payable bi-weekly.","One-time grant of 500,000 restricted stock units (RSUs) under standard vesting schedule.","If involuntarily terminated within 12 months of a change of control, consultant receives lump sum equal to 3x fair market value of all equity held.","Consulting term effective July 20, 2025, with services deemed to have started March 3, 2025 (CEO appointment date).","Agreement can be terminated by either party with 60 days' notice; change-of-control definition includes reverse mergers, SPAC transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162333,"accession_number":"0001213900-25-055188","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Abpro Holdings postpones 2025 annual meeting to later date","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board voted to postpone annual meeting originally scheduled for June 17, 2025.","New meeting date and record date to be determined; company will deliver new notice.","No reason for postponement disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162332,"accession_number":"0001213900-25-035735","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Abpro/Celltrion ABP-102/CT-P72 preclinical data at AACR 2025 shows potential best-in-class HER2 x CD3 T-cell engager","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ABP-102/CT-P72 preclinical data presented orally at AACR 2025; co-developed with Celltrion via strategic partnership.","Up to 2-fold increase in tumor suppression vs. runimotamab biosimilar in HER2-overexpressing cancer models.","Reduced cytokine release and tolerated >180x the MTD of parental antibody in monkeys, suggesting wider therapeutic window.","Phase 1 clinical trials planned to commence in first half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162331,"accession_number":"0001213900-25-035075","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Abpro amends conversion price definition in Yorkville convertible note to fix scrivener's error","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment corrects 'Conversion Price' to lower of $11.50 fixed or 94% of lowest daily VWAP over 5 consecutive trading days.","Yorkville note originally issued Nov 13, 2024 for $3M; net proceeds $2.755M.","All other terms of the November 2024 note remain unchanged.","Effective April 20, 2025; executed by Abpro CEO Miles Suk and Yorkville."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162330,"accession_number":"0001213900-25-032584","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Abpro Holdings receives Nasdaq deficiency notices: MVPHS below $15M, MVLS below $50M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received two Nasdaq deficiency notices on April 10, 2025: MVPHS below $15M and MVLS below $50M.","Has 180 calendar days (until October 7, 2025) to regain compliance for each requirement.","To regain MVPHS compliance, MVPHS must close at $15M+ for 10 consecutive business days; MVLS similarly at $50M+.","Failure could lead to delisting; company may appeal or consider transfer to Nasdaq Capital Market.","Company intends to monitor and take reasonable measures; no immediate effect on trading of ABP and ABPWW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162329,"accession_number":"0001213900-25-032083","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Abpro Holdings restates FY22, FY23, Q3 2024 due to $3.3M liability understatement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee concluded prior-period financials should no longer be relied upon.","Estimated $3.3 million increase to accrued expenses, total liabilities, and accumulated deficit per period.","Error arose from understatement of liabilities under a license agreement.","Company will file restated financials in 2024 Form 10-K, not amend prior filings.","Discussed the matter with auditor Wolf & Company, P.C."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162328,"accession_number":"0001213900-25-029934","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Abpro shareholders approve >20% stock issuance to Yorkville under SEPA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting April 8, 2025; quorum of 50.7% of shares represented.","Proposal passed with 26,359,504 votes for (99.99% of votes cast), 2,827 against, 1,114 abstentions.","SEPA allows issuance of shares exceeding 20% of outstanding common stock as of Oct 30, 2024.","Approval satisfies Nasdaq Listing Rule 5635(d) for the Yorkville financing arrangement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162327,"accession_number":"0001213900-25-029927","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Abpro Holdings receives Nasdaq minimum bid price deficiency notice; 180-day cure period.","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 2, 2025, for failure to meet $1.00 minimum bid price requirement.","Closing bid price below $1.00 for 30 consecutive business days triggers the deficiency.","Company has 180 calendar days, until September 29, 2025, to regain compliance.","To regain compliance, common stock must close at $1.00+ for 10 consecutive business days.","If not cured by Sept 29, may qualify for an additional 180-day compliance period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180347,"accession_number":"0001013762-25-002718","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Abpro to present first preclinical data for bispecific HER2 x CD3 T-cell engager at AACR 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oral presentation of ABP-102/CT-P72 at AACR 2025 in New Drugs on the Horizon session on April 27, 2025.","ABP-102/CT-P72 is a tetravalent bispecific HER2 x CD3 T-cell engager developed under a strategic partnership with Celltrion.","Data are under embargo until presentation; no results disclosed.","Presenter: Adam J. Pelzek, Ph.D., Associate Director at Abpro."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180346,"accession_number":"0001213900-25-021806","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Abpro terminates CEO Ian Chan, appoints Miles Suk as new CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ian Chan terminated as CEO and principal executive officer, effective March 3, 2025.","Chan also removed as CEO and director of subsidiary Abpro Corporation.","Miles Suk signed as Chief Executive Officer in the March 7 filing, indicating his appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180345,"accession_number":"0001213900-25-021184","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["3.03","9.01"],"status":"ready","headline":"Abpro Holdings adjusts warrant exercise price to $3.83 and redemption trigger to $5.99","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrant exercise price reduced from $11.50 to $3.83 per share, effective March 5, 2025.","Redemption trigger price lowered from $18.00 to $5.99 per share, representing 180% of $3.33.","Adjustments required after business combination closed Nov 13, 2024; Market Value was $3.2835.","Newly Issued Price for shares issued in connection with business combination was $3.33 per share.","Warrants (ABPWW) and common stock (ABP) trade on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180344,"accession_number":"0001213900-25-016110","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Abpro provides pipeline update; Celltrion partnership for ABP-102 fully funded with up to $1.75B milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Celltrion funds all development of ABP-102 (HER2/CD3 T-cell engager) for breast/gastric cancer; Abpro retains 50% profit share.","ABP-201 (VEGF/ANG2) for Wet AMD/DME: IND filing expected Q1 2026, Phase 1 start same year.","ABP-102 IND filing targeted for 2H 2025; Phase 1 initiation in 1H 2026.","Additional pipeline: ABP-150 (Claudin18.2/CD3) and ABP-110 (GPC3/CD3) IND filings in 2026, Phase 1 in 2027.","No financial results; presentation highlights platform, preclinical data, and upcoming milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197158,"accession_number":"0001213900-24-108370","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Abpro celebrates business combination close; raises $10M and secures $50M equity facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Business combination with ACAB closed Nov 13, 2024; Nasdaq bell ringing ceremony held Dec 12.","Raised $10M gross proceeds ($7M PIPE + $2.76M convertible note) and secured up to $50M equity facility from Yorkville.","Funds to support development of antibody pipeline for HER2+ cancers, wet AMD, DME, and infectious diseases.","Partnered with Celltrion to advance ABP 102 T-cell engager for HER2+ breast, gastric, pancreatic cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197157,"accession_number":"0001213900-24-107083","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Abpro Holdings dismisses Marcum as auditor; engages Wolf & Company; cites material weaknesses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Dec 9, 2024, Abpro dismissed Marcum LLP and engaged Wolf & Company as independent auditor.","No disagreements on accounting principles or audit scope; decision approved by Audit Committee.","Marcum's prior audit reports (FY 2022 & 2023) expressed substantial doubt about going concern.","Material weaknesses: failure to timely file tax returns, trust cash used for taxes/operations, over-accrual of expenses.","Marcum furnished a letter to SEC agreeing with the statements in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197156,"accession_number":"0001213900-24-103612","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-11-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Abpro CFO Shahraab Ahmad resigns effective Nov 22, 2024","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Shahraab Ahmad notified the company of his resignation as CFO on Nov 21, 2024.","Resignation effective November 22, 2024; no replacement named.","No reason for departure or transition plan disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197155,"accession_number":"0001213900-24-102382","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["1.01","2.01","9.01","5.02","3.02","2.03","3.03","5.01","5.03","5.06"],"status":"ready","headline":"Abpro Holdings completes de-SPAC merger with Abpro Corporation; stock begins trading Nov 14","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger Consideration ~$500M: ~50M shares issued (39.1M to Abpro shareholders, 10.9M reserved for rollover RSUs/options).","~330k ACAB public shares redeemed at ~$11.36/share for aggregate $3.75M; trust account held $2.38M pre-closing.","PIPE Offering raised $7.0M via 1.12M shares + 2.24M incentive shares; cancelled ~$4.22M of Abpro debt.","Lock-up agreements for Abpro shareholders: 12-month lock-up period from closing.","New common stock (ABP) began trading on Nasdaq Global Market on Nov 14; warrants (ABPWW) on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197154,"accession_number":"0001193125-24-257374","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Abpro Holdings completes SPAC merger; to trade on Nasdaq under 'ABP' starting Nov. 14","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Business combination between Abpro Corporation and Atlantic Coastal Acquisition Corp. II closed; approved by Atlantic Coastal stockholders on Nov. 7.","Common stock to trade on Nasdaq Global Market under 'ABP'; warrants on Nasdaq Capital Market under 'ABPWW' beginning Nov. 14, 2024.","Celltrion invested $5 million in a PIPE transaction and gained a board seat (Soo Young Lee).","Abpro focuses on next-gen antibody therapies for HER2+ cancers, Wet AMD/DME, and COVID-19 using DiversImmune platform.","Exclusive collaboration with Celltrion on ABP 102 (t-cell engager) for HER2+ breast, gastric, and pancreatic cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197165,"accession_number":"0001193125-24-254113","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Atlantic Coastal corrects redemption price to $11.34 per share in Abpro merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Redemption price per Series A share corrected from $11.28 to $11.34 in connection with Abpro business combination.","Correction appears in two prior 8-Ks filed Nov 8, 2024; this 8-K supersedes both with respect to that typo.","No other disclosures amended; estimated redemption based on Trust Account balance after taxes as of Nov 8, 2024.","Atlantic Coastal Acquisition Corp. II (ticker ACAB) is merging with Abpro Corporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197164,"accession_number":"0001193125-24-253672","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"ACAB enters forward purchase deal for up to 500K shares; 80.5% of public shares seek redemption","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Forward Purchase Agreement with YA II PN for up to 500,000 recycled shares; prepayment from trust at ~$11.28/share.","As of Nov 8, 2024, 436,019 ACAB public shares (80.55%) elected redemption; estimated $11.28 per share redemption price.","Seller waives redemption rights on recycled shares during term of Forward Purchase Agreement.","Reset Price initially $10.00, subject to weekly adjustment to lowest of current Reset Price, $10.00, or 3-day VWAP.","Transaction structured to comply with tender offer rules (Rule 14e-5) and support Business Combination with Abpro."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197163,"accession_number":"0001193125-24-253658","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"ACAB stockholders approve all proposals for Abpro business combination; 436K shares redeemed at ~$11.28","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 9 proposals passed with 7,587,598 votes for and 20,710 against (99.7% approval).","436,019 public shares redeemed at approx. $11.28 per share in connection with the special meeting.","Proposals included business combination, charter amendments, director election, and stock plan.","The de-SPAC transaction with Abpro Corporation now has stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197162,"accession_number":"0001193125-24-251745","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ACAB enters non-redemption deal to reduce redemptions up to 124K shares before Abpro vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-redemption agreement with Sandia Investment Management LP covering up to 124,352 shares.","Investor rescinds redemption demands; receives payment of redemption price minus $9.00 per share at close.","Abpro guarantees reimbursement to investor if business combination not closed by Nov 20, 2024.","Special meeting to approve business combination scheduled for November 7, 2024.","Agreement is intended to reduce redemptions and support closing of the Abpro merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197161,"accession_number":"0001193125-24-250197","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"ACAB enters $50M equity line and $5M prepaid advance with Yorkville for post-merger financing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$5M prepaid advance via convertible notes with 8% original issue discount; $3M at merger close, $2M after registration effective and shareholder approval.","Post-close equity line of up to $50M: Yorkville buys shares at 96-97% of VWAP, subject to 4.99% beneficial ownership cap and 19.99% exchange cap for pre-paid shares.","Conversion price for notes: lower of $11.50 (subject to adjustment) or 94% of 5-day low VWAP, with floor at 20% of closing price on issuance or S-1 effective date.","Yorkville receives $500K in shares as commitment fee; amortization events trigger monthly payments of $1.25M principal plus 5% premium.","Proxy statement supplemented to disclose Yorkville financing and substantial dilution risks; shareholder approval may be sought for exchange cap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197160,"accession_number":"0001193125-24-240485","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Atlantic Coastal gets Nasdaq delisting notice, extends SPAC deadline to Nov 19; S-4 effective for Abpro deal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq delisting determination on Oct 16, 2024 for failure to meet market value of publicly held shares, round lot holders, and minimum publicly held shares requirements.","Company intends to request a hearing by Oct 23, 2024 to stay suspension; expects to regain compliance upon closing of business combination with Abpro.","Board extended deadline to complete a business combination from Oct 19, 2024 to Nov 19, 2024.","S-4 registration statement for the Abpro business combination became effective on Oct 18, 2024.","Nasdaq also noted failure to maintain 750,000 publicly held shares as of Sep 10, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197159,"accession_number":"0001193125-24-237574","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ACAB files amended S-4, revised Abpro presentation; no new financial specifics","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed amendment to Registration Statement on Form S-4 with SEC on Oct 9, 2024, for Abpro business combination.","Revised investor presentation furnished as Exhibit 99.1; excerpted text contains only disclaimers, no substantive data.","No specific deal valuation, financial projections, or timeline updates were provided in the filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213413,"accession_number":"0001193125-24-222871","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Atlantic Coastal Acquisition Corp. II shareholders approve extension to Nov 19, 2024; 126,122 shares redeemed at ~$11.27","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Charter amendment extends business combination deadline from Sep 19 to Oct 19, 2024, with optional further monthly extension to Nov 19, 2024.","Sponsor must deposit $0.03 per non-redeemed public share into trust for each monthly extension.","Proposal approved with 517,796 votes for, 20,710 against, 0 abstain; no broker non-votes.","Holders of 126,122 public shares redeemed at approx. $11.27 per share in connection with the vote.","Company had 538,506 shares represented at the special meeting, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213412,"accession_number":"0001193125-24-213240","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"ACAB amends Abpro merger to issue 600,601 shares to sponsor in lieu of $2M cash payment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ACAB will issue 600,601 shares of Series A common stock to its sponsor Atlantic Coastal Management II LLC, replacing $2,000,000 of Unpaid SPAC Expenses.","The shares are issued under Regulation D as unregistered equity; surviving company must file a resale registration statement within 60 to 90 days after closing.","An additional 350,000 shares of Series A common stock will be issued to Pillsbury Winthrop Shaw Pittman LLP as service provider shares, also requiring registration.","Remaining Unpaid SPAC Expenses up to $600,000 due to sponsor will be paid in cash from the trust account or by the surviving company at closing.","The amendment modifies the Business Combination Agreement dated December 11, 2023, with no other changes to the original terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213411,"accession_number":"0001193125-24-208786","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"ACAB enters PIPE agreements for $11.2M with Abpro Bio and Celltrion for business combination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abpro Bio subscribes for 622,467 shares at $10/share ($6.2M total), with $4.2M portion via loan forgiveness.","Celltrion subscribes for 500,000 shares at $10/share ($5M total).","Both investors receive incentive shares: 1,244,934 for Abpro Bio and 1,000,000 for Celltrion.","Closing conditioned on previously announced business combination with Abpro Corporation.","Celltrion gets investor rights including director nominee designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213410,"accession_number":"0001193125-24-202807","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SPAC extends business combination deadline by one month to Sep 19, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board extended deadline from August 19, 2024 to September 19, 2024 via resolution on Aug 16, 2024.","Atlantic Coastal Acquisition Corp. II is a SPAC traded on Nasdaq under symbol ACABU.","Extension provides additional time to complete an initial business combination.","No other material events or changes disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213409,"accession_number":"0001193125-24-194969","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Atlantic Coastal Acquisition Corp. II receives Nasdaq delisting notice for failing minimum 400 holders","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on July 31, 2024 for non-compliance with Listing Rule 5450(a) requiring minimum 400 holders of record.","Company has 45 calendar days to submit a compliance plan to Nasdaq.","Up to 180 calendar days from the notice date to regain compliance.","Company plans to submit its compliance plan within the required timeframe."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213408,"accession_number":"0001193125-24-181645","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Atlantic Coastal Acquisition Corp. II extends business combination deadline to August 19, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board extended the deadline from July 19, 2024 to August 19, 2024 (one month).","Extension provides additional time to complete a business combination.","Failure to complete deal by new deadline may result in liquidation; extension is routine for SPACs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232606,"accession_number":"0001193125-24-163436","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Atlantic Coastal Acquisition Corp. II extends business combination deadline to July 19, 2024","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Board extended deadline from June 19, 2024 to July 19, 2024.","Extension approved by board resolution on June 14, 2024.","Deadline for completing initial business combination extended by one month."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232605,"accession_number":"0001193125-24-157395","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Nasdaq notifies Atlantic Coastal Acquisition Corp II of non-compliance for late Q1 2024 filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on June 3, 2024 for failure to timely file Q1 2024 Form 10-Q (due May 15).","Company had previously filed NT 10-Q on May 15 but still requires additional time to finalize financial statements.","Has 60 calendar days to submit a specific plan to Nasdaq to regain compliance with Listing Rule 5250(c)(1).","Company expects to file the Report in the coming weeks and is working diligently to complete it."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232604,"accession_number":"0001193125-24-151928","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ACAB enters expense advancement agreement with sponsor for up to $600k","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sponsor advances up to $600,000 aggregate, including $240,000 previously advanced, interest-free.","Advances due on demand; upon business combination, sponsor may deem repaid or treat as Unpaid SPAC Expenses.","Funds used for working capital, stock redemptions, and costs related to Abpro Corporation merger.","Each advance evidenced by a promissory note; notes accrue no interest and are repayable on demand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232603,"accession_number":"0001193125-24-141711","cik":1893219,"company_name":"Abpro Holdings, Inc.","ticker":"ABPO","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Atlantic Coastal Acquisition Corp. II extends business combination deadline to June 19, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board resolution extended the deadline from May 19, 2024 to June 19, 2024.","SPAC has not yet completed a business combination; extension provides additional month to find target.","Tickers: ACABU (units), ACAB (common), ACABW (warrants)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}